China is accelerating research into vaccines and tests to cope with possible future Omicron variant outbreaks amid global concern about its potential damage.
Sino Biological, a Beijing-based company specialising in recombinant protein production, antibody development and the manufacture of test reagents, announced on Thursday it had developed a key part of the recombinant spike protein of the Omicron variant that could be used to test the efficacy of Covid-19 vaccines and antibodies.
Already a subscriber? Log in.
Get 30% off with our ads free Premium Plan!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
